{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T18:51:54Z","timestamp":1787251914075,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s12072-026-11070-y","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T18:49:08Z","timestamp":1774378148000},"page":"838-851","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Gemcitabine-cisplatin plus durvalumab in advanced intrahepatic cholangiocarcinoma: effectiveness outcomes and characterization of the tumor microenvironment"],"prefix":"10.1007","volume":"20","author":[{"given":"Jiawei","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Decai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"issue":"3","key":"11070_CR1","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3350\/cmh.2021.0287","volume":"28","author":"M Komuta","year":"2022","unstructured":"Komuta M. Intrahepatic cholangiocarcinoma: tumour heterogeneity and its clinical relevance. Clin Mol Hepatol. 2022;28(3):396\u2013407","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"11070_CR2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","volume":"7","author":"PJ Brindley","year":"2021","unstructured":"Brindley PJ, et al. Cholangiocarcinoma. Nat Rev Dis Primers. 2021;7(1):65","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"11070_CR3","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41575-022-00741-4","volume":"20","author":"TF Greten","year":"2023","unstructured":"Greten TF, et al. Immunology and immunotherapy of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2023;20(6):349\u2013365","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"14","key":"11070_CR4","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u20131281","journal-title":"N Engl J Med"},{"issue":"15","key":"11070_CR5","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v31.i15.104901","volume":"31","author":"J-J Liu","year":"2025","unstructured":"Liu J-J, et al. Conversion treatment for advanced intrahepatic cholangiocarcinoma: opportunities and challenges. World J Gastroenterol. 2025;31(15): 104901","journal-title":"World J Gastroenterol"},{"issue":"1","key":"11070_CR6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/jhbp.1219","volume":"30","author":"T Ioka","year":"2023","unstructured":"Ioka T, et al. Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA). J Hepatobiliary Pancreat Sci. 2023;30(1):102\u2013110","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"6","key":"11070_CR7","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","volume":"5","author":"RT Shroff","year":"2019","unstructured":"Shroff RT, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial. JAMA Oncol. 2019;5(6):824\u2013830","journal-title":"JAMA Oncol"},{"issue":"8","key":"11070_CR8","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.jvir.2013.02.031","volume":"24","author":"S Mouli","year":"2013","unstructured":"Mouli S, et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vascular and Interventional Radiol\u202f: JVIR. 2013;24(8):1227\u20131234","journal-title":"J Vascular and Interventional Radiol : JVIR"},{"key":"11070_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010012","author":"DC Jones","year":"2025","unstructured":"Jones DC, et al. LILRB2 blockade facilitates macrophage repolarization and enhances T cell-mediated antitumor immunity. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2024-010012","journal-title":"J Immunother Cancer"},{"issue":"10391","key":"11070_CR10","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England). 2023;401(10391):1853\u20131865","journal-title":"Lancet (London, England)"},{"issue":"8","key":"11070_CR11","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","volume":"9","author":"D-Y Oh","year":"2024","unstructured":"Oh D-Y, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. The Lancet Gastroenterol Hepatol. 2024;9(8):694\u2013704","journal-title":"The Lancet Gastroenterol Hepatol"},{"issue":"8","key":"11070_CR12","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"D-Y Oh","year":"2022","unstructured":"Oh D-Y, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8): EVIDoa2200015","journal-title":"NEJM Evid"},{"issue":"3","key":"11070_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101290","volume":"7","author":"Z Li","year":"2025","unstructured":"Li Z, et al. Recent advances in systemic therapy for advanced biliary tract cancer: a systematic review and meta-analysis using reconstructed RCT survival data. JHEP Rep. 2025;7(3): 101290","journal-title":"JHEP Rep"},{"key":"11070_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.05.003","author":"DY Oh","year":"2025","unstructured":"Oh DY, et al. Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study. J Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.jhep.2025.05.003","journal-title":"J Hepatol"},{"issue":"10","key":"11070_CR15","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1002\/cac2.12480","volume":"43","author":"S Ren","year":"2023","unstructured":"Ren S, et al. Intratumoral CD103+ CD8+ T cells predict response to neoadjuvant chemoimmunotherapy in advanced head and neck squamous cell carcinoma. Cancer Commun (London, England). 2023;43(10):1143\u20131163","journal-title":"Cancer Commun (London, England)"},{"key":"11070_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101170","volume":"50","author":"L Rimassa","year":"2025","unstructured":"Rimassa L, et al. New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe. Lancet Reg Health Eur. 2025;50: 101170","journal-title":"Lancet Reg Health Eur"},{"issue":"2","key":"11070_CR17","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000531458","volume":"13","author":"C Yoo","year":"2024","unstructured":"Yoo C, Hyung J, Chan SL. Recent advances in systemic therapy for advanced intrahepatic cholangiocarcinoma. Liver Cancer. 2024;13(2):119\u2013135","journal-title":"Liver Cancer"},{"issue":"11","key":"11070_CR18","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/cac2.12345","volume":"42","author":"K Cheng","year":"2022","unstructured":"Cheng K, et al. Tumor-associated macrophages in liver cancer: from mechanisms to therapy. Cancer Commun (London, England). 2022;42(11):1112\u20131140","journal-title":"Cancer Commun (London, England)"},{"key":"11070_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.874589","volume":"13","author":"Y Pu","year":"2022","unstructured":"Pu Y, Ji Q. Tumor-associated macrophages regulate PD-1\/PD-L1 immunosuppression. Front Immunol. 2022;13: 874589","journal-title":"Front Immunol"},{"issue":"1","key":"11070_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo W, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165(1):35\u201344","journal-title":"Cell"},{"issue":"2","key":"11070_CR21","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.cmet.2019.05.016","volume":"30","author":"Z Hu","year":"2019","unstructured":"Hu Z, et al. Acylglycerol kinase maintains metabolic state and immune responses of CD8(+) T cells. Cell Metab. 2019;30(2):290-302.e5","journal-title":"Cell Metab"},{"issue":"12","key":"11070_CR22","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1016\/j.celrep.2016.08.056","volume":"16","author":"DM Newman","year":"2016","unstructured":"Newman DM, et al. Acetylation of the Cd8 locus by KAT6A determines memory T cell diversity. Cell Rep. 2016;16(12):3311\u20133321","journal-title":"Cell Rep"},{"issue":"2","key":"11070_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.108957","volume":"27","author":"Z Xia","year":"2024","unstructured":"Xia Z, et al. EP300 restores the glycolytic activity and anti-tumor function of CD8(+) cytotoxic T cells in nasopharyngeal carcinoma. iScience. 2024;27(2): 108957","journal-title":"iScience"},{"key":"11070_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.101040","volume":"73","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, et al. NDRG1 overcomes resistance to immunotherapy of pancreatic ductal adenocarcinoma through inhibiting ATG9A-dependent degradation of MHC-1. Drug Resist Updat. 2024;73: 101040","journal-title":"Drug Resist Updat"},{"issue":"6","key":"11070_CR25","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1053\/j.gastro.2024.07.008","volume":"167","author":"S Rahmani","year":"2024","unstructured":"Rahmani S, et al. Gluten-dependent activation of CD4(+) T cells by MHC class II-expressing epithelium. Gastroenterology. 2024;167(6):1113\u20131128","journal-title":"Gastroenterology"},{"issue":"3","key":"11070_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101290","volume":"7","author":"Z Li","year":"2024","unstructured":"Li Z, et al. Recent advances in systemic therapy for advanced biliary tract cancer: a systematic review and meta-analysis using reconstructed RCT survival data. JHEP Rep\u202f: Innovation In Hepatol. 2024;7(3): 101290","journal-title":"JHEP Rep : Innovation In Hepatol"},{"issue":"8","key":"11070_CR27","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh DY, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8):EVIDoa2200015","journal-title":"NEJM Evid."},{"issue":"3","key":"11070_CR28","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.21873\/invivo.13974","volume":"39","author":"Y Tagayasu","year":"2025","unstructured":"Tagayasu Y, et al. Conversion surgery performed following durvalumab combined with gemcitabine and cisplatin in cholangiocarcinoma: a case report. In Vivo. 2025;39(3):1724\u20131730","journal-title":"In Vivo"},{"issue":"5","key":"11070_CR29","first-page":"407","volume":"52","author":"N Mitsui","year":"2025","unstructured":"Mitsui N, et al. Complete response achieved by Gemcitabine+Cisplatin+Durvalumab therapy for lymph node recurrence of intraductal cholangiocarcinoma-a case report. Gan To Kagaku Ryoho. 2025;52(5):407\u2013409","journal-title":"Gan To Kagaku Ryoho"},{"key":"11070_CR30","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-17282-0","author":"N Shah","year":"2025","unstructured":"Shah N, et al. A multimodality treatment strategy for an intrahepatic cholangiocarcinoma and complex liver resection with vascular reconstruction-a video vignette. Ann Surg Oncol. 2025. https:\/\/doi.org\/10.1245\/s10434-025-17282-0","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"11070_CR31","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1053\/j.gastro.2023.10.022","volume":"166","author":"C Hu","year":"2024","unstructured":"Hu C, et al. Tertiary lymphoid structure-associated B cells enhance CXCL13(+)CD103(+)CD8(+) tissue-resident memory T-cell response to programmed cell death protein 1 blockade in cancer immunotherapy. Gastroenterology. 2024;166(6):1069\u20131084","journal-title":"Gastroenterology"},{"issue":"6717","key":"11070_CR32","doi-asserted-by":"publisher","DOI":"10.1126\/science.abq7248","volume":"386","author":"A Hayday","year":"2024","unstructured":"Hayday A, et al. Cancer immunotherapy by \u03b3\u03b4 T cells. Science. 2024;386(6717): eabq7248","journal-title":"Science"},{"issue":"4","key":"11070_CR33","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.jcmgh.2023.01.006","volume":"15","author":"F Ying","year":"2023","unstructured":"Ying F, Chan MSM, Lee TKW. Cancer-associated fibroblasts in hepatocellular carcinoma and cholangiocarcinoma. Cell Mol Gastroenterol Hepatol. 2023;15(4):985\u2013999","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"11070_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.655152","volume":"9","author":"X Geng","year":"2021","unstructured":"Geng X, et al. Cancer-associated fibroblast (CAF) heterogeneity and targeting therapy of CAFs in pancreatic cancer. Front Cell and Develop Biol. 2021;9: 655152","journal-title":"Front Cell and Develop Biol"},{"issue":"7","key":"11070_CR35","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/s41416-020-0744-7","volume":"122","author":"T Yamanaka","year":"2020","unstructured":"Yamanaka T, et al. Nintedanib inhibits intrahepatic cholangiocarcinoma aggressiveness via suppression of cytokines extracted from activated cancer-associated fibroblasts. Br J Cancer. 2020;122(7):986\u2013994","journal-title":"Br J Cancer"},{"issue":"1","key":"11070_CR36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12943-023-01860-5","volume":"22","author":"H Zhang","year":"2023","unstructured":"Zhang H, et al. Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials. Mol Cancer. 2023;22(1):159","journal-title":"Mol Cancer"},{"issue":"3","key":"11070_CR37","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.jhep.2023.05.010","volume":"79","author":"JL Tomlinson","year":"2023","unstructured":"Tomlinson JL, Valle JW, Ilyas SI. Immunobiology of cholangiocarcinoma. J Hepatol. 2023;79(3):867\u2013875","journal-title":"J Hepatol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11070-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-026-11070-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11070-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T05:58:00Z","timestamp":1783144680000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-026-11070-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["11070"],"URL":"https:\/\/doi.org\/10.1007\/s12072-026-11070-y","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}